Aldeyra submitted the single successful trial to the FDA over the summer and the agency accepted the resubmitted NDA for ...
FDA extends Aldeyra's reproxalap PDUFA date to March 2026 after a major NDA amendment tied to new clinical study report data.
The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for Aldeyra’s New Drug Application (NDA) for reproxalap for the treatment of dry ...
Stocktwits on MSN
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision?
The FDA delayed its decision on the dry eye drug Reproxalap without raising new issues. ・The FDA pushed the PDUFA deadline to ...
Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback